New Delhi, January 22, 2025 : Agilus Diagnostics, India’s largest and most trusted diagnostic network, announces a ground-breaking achievement in genomic testing with its industry-leading 3-day turnaround time (TAT) for test results in myeloid malignancies.
The genomic testing market in India is experiencing rapid growth, driven by advancements in technology, increasing awareness, and the rising demand for personalized medicine. Currently valued at approximately USD 150 million, the market is projected to grow at a CAGR of over 15% in the next five years. Genomic testing is transforming cancer diagnostics by revolutionizing targeted therapy and personalized medicine. By providing actionable insights into an individual’s unique genetic profile, it enables clinicians to identify specific mutations, tailor treatment plans, and select therapies that offer the highest efficacy. As the future of cancer diagnostics, genomic testing empowers early detection, precise interventions, and better disease management, marking a significant shift in how cancer care is delivered. With these advancements, Agilus Diagnostics’ cutting-edge offerings place it at the forefront of this expanding market. By delivering unparalleled speed and precision, the company is well-positioned to capitalize on the growing demand for genomic testing in India, establishing itself as a leader in the space.
Next Generation Sequencing (NGS) is revolutionizing genetic testing by enabling precise, comprehensive analysis of genetic variations, empowering clinicians with actionable insights for personalized patient care. While genomic testing has traditionally been a lengthy process, often taking weeks to deliver results, Agilus Diagnostics has set a new benchmark by delivering individualized reports—meticulously crafted by expert molecular pathologists—in just three days (for myeloid malignancies). This rapid turnaround ensures faster clinical decision-making, ultimately improving patient outcomes and setting us apart as leaders in precision diagnostics.
The Myeloid Genomics Testing and Precision Assay is designed to offer faster, more precise insights into cancer and myeloid disorders. The Myeloid Genomics Testing covers 79 genes, including those linked to inherited risks, to detect key genetic changes like mutations and fusions. This enables personalized treatment recommendations for conditions like Acute Myeloid Leukemia (AML) and Myeloproliferative Neoplasms (MPN). Reports are reviewed by expert pathologists and include internationally recognized risk assessment tools and therapy suggestions tailored to the patient.
The Genomic Profiling Precision Assay provides comprehensive genomic profiling for cancers like lung, colon, breast, and melanoma by analyzing 50 critical genes. It identifies mutations, amplifications, and fusion genes, offering actionable insights for targeted treatments. With optimized panels for tissue and blood samples, the test ensures accurate results within 2 days for liquid biopsy samples and 7 days for tissue block samples, making it a powerful tool for precision medicine.
“Our 3-day genomic testing initiative for myeloid malignancies addresses one of the biggest challenges in precision oncology —Time. With this breakthrough, Agilus Diagnostics is not only setting a new industry standard but also transforming patient care by enabling faster diagnoses and treatment,” said Dr. Anand K, Managing Director & CEO of Agilus Diagnostics.
Currently, the labs in the genomic testing space often take up to 2 -3 weeks to deliver results for myeloid malignancies, which can delay critical clinical decisions. In contrast, Agilus Diagnostics’ rapid testing approach significantly shortens the diagnostic timeline, reducing hospital visits and enhancing the patient experience.
Driving Global Standards in Genomic Testing
Agilus Diagnostics’ commitment to speed and precision extends beyond technological advancements. The company ensures that every report is individualized, with expert molecular pathologists meticulously interpreting results. This personalized reporting approach ensures that physicians receive not just data but clinically actionable insights that support timely and effective patient management.
Agilus Diagnostics is setting new benchmarks in genomic testing, aligning with global standards in personalized medicine. The combination of advanced technology, rapid turnaround times, and expert oversight positions the company as a leader in precision diagnostics. By offering unparalleled speed, accuracy, and patient-focused care, Agilus Diagnostics reaffirms its commitment to bringing world-class diagnostic services to India.
“With our advanced genomic testing capabilities, we aim to provide clinicians with the tools they need to make timely, informed decisions. This not only improves outcomes but also sets a new benchmark for the healthcare industry in India,” added Dr. Anand K.
Agilus Diagnostics’ industry-leading solutions continue to pave the way for innovations in healthcare, ensuring that Indian patients have access to cutting-edge diagnostic services that meet global standards.
